#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Personalized medicine in diabetology in the context of consensual statement of the ADA/EASD 2015


Authors: Vladimír Uličiansky 1;  Zbynek Schroner 2;  Zuzana Némethyová 3;  Peter Galajda 4;  Marián Mokáň 4
Authors‘ workplace: Via medica s. r. o., Košice 1;  SchronerMED s. r. o., Košice 2;  Dia centrum plus, s. r. o., Bratislava 3;  I. interná klinika JLF UK a UNM, Martin 4
Published in: Forum Diab 2015; 4(2): 102-118
Category: Main Theme: Review

Overview

The patient centred approach provides health care that is respectful of and responsive to individual patient preferences, needs, and values, and ensuring that patient values guide all clinical decisions. In their study the authors discuss the approach to defining glycemic targets and to the treatment of patients with type 2 diabetes mellitus in the context of new findings and of the consensual statement of the American Diabetes Association and the European Association for the Study of Diabetes (ADA/EASD) 2015.

Key words:
patient-centred approach – type 2 diabetes mellitus - glycemic targets – pharmacotherapy


Sources

1. Uličiansky V, Schroner Z, Galajda P et al. Algoritmus liečby diabetes mellitus 2. typu 2011 v klinickej praxi. Diabetes a obezita 2011; 11(22): 9–32.

2. Pozzilli P, Leslie RD, Chan J et al. The A1C and ABCD of glycaemia management in type 2 diabetes: a phycisian´s personalized approach. Diabetes Metab Res Rev 2010; 26(4): 239–244.

3. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of Hyperglycemia in Type 2 Diabetes. A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35(6): 1364–1379.

4. Raz I, Ridle MC, Rosenstock J et al. Personalized Management of Hyperglycemia in Type 2 Diabetes. Reflection from a Diabetes Care Editors´ Expert Forum. Diabetes Care 2013; 36(6): 1779–1788.

5. Škrha J. Úskalí současných poznatků v terapii. In: Škrha J. Cesta diabetologie aneb Kde vše začíná a končí. Maxdorf Jessenius: Praha 2014: 61–87. ISBN 9788073453855.

6. Matthews DR. Wisdom-based and evidence-based medicine. Diabetes Obes Metab 2012; 14(Suppl 1): 1–2.

7. Uličiansky V. Personalizovaná medicína. In: Uličiansky V (ed). Diabetes mellitus v zrelom veku. Quick Print: Martin 2013: 34–46.

8. Topolčan O, Kinkorová J. Personalizovaná medicína. Klin Farmakol Far 2012; 26(3): 121–122.

9. Sadee W. Genomics and personalized medicine. Int J Pharm 2011; 415(1–2): 2–4.

10. Florence AT, Lee VHL: Personalised medicines: More tailored drugs, more tailored delivery. Int J Pharm 2011; 415(1–2): 29–33.

11. Chen R, Mias GI, Li-Pook-Than J et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012; 148(6): 1293–1307.

12. Smith RJ, Nathan DM, Arslanian SA et al. Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J Clin Endocrinol Metab 2010; 95(4): 1566–1574.

13. European Commission. Research & Innovation – Health. Towards Personalised Medicine. Dostupné z http: <http://ec.europa.eu/research/health/policy-issues-personalised-medicine_en.html>.

14. Mullan RJ, Montori VM, Shah ND et al. The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med 2009; 169(17): 1560–1568.

15. Ďuriš I, Hulín I, Bernardič M. Editorial. In: Ďuriš I, Hulín I, Bernardič M. Princípy internej medicíny 1. Slovak Academic Press: Bratislava 2001. ISBN 80–88908–69–8.

16. Nathan M, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52(1): 17–30.

17. Inzuchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38(1):140–149.

18. American Diabetes Association. Standards of medical care in diabetes – 2015. 6. Glycemic Targets. Diabetes Care 2015; 38(Suppl 1): S33–S40. Dostupné z DOI: <http://dx.doi.org/10.2337/dc15-S009>.

19. AACE/ACE Diabetes Guidelines. Endocr Pract 2015; 21(Suppl 1):4. Dostupné z WWW: <https://www.aace.com/files/dm-guidelines-ccp.pdf>.

20. Ismail-Beigi F, Moghissi E, Tiktin E et al. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011; 154(8): 554–559.

21. Uličiansky V. Algoritmus liečby diabetes mellitus 2. typu. Via medica: Košice 2008. ISBN 978–80–970058–3-2.

22. Staník J, Gašperíková D, Klimeš I. Monogénový diabetes mellitus. In: Staník J, Gašperíková D, Klimeš I. Monogénové poruchy sekrécie a účinku inzulínu. Univerzita Komenského: Bratislava 2015. ISBN 978–80–223–3803–5.

23. Schroner Z, Javorsky M, Tkacova R et al. Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13(1): 89–91.

24. Javorský M, Klimčáková L, Schroner Z et al. KCN11 gene E23K variant and therapeutic response to sulfonylureas. Eur J Intern Med 2012; 23(3): 245–249.

25. Tkáč I, Javorský M, Klimčáková L et al. A pharmacogenetic association between a variation in calpain 10 (CAPN10) gene and the response to metformin treatment in patients with type 2 diabetes. Eur J Clin Pharmacol 2015; 71(1): 59–63.

26. Smushkin G, Sathananthan M, Sathananthan A et al. Diabetes-associated common genetic variation and its association with GLP-1 concentrations and response to exogenous GLP-1. Diabetes 2012; 61(5): 1082–1089.

27. Tsapas A, Matthews DR. N of 1 trials in diabetes: making individual therapeutic decisions. Diabetologia 2008; 51(6): 921–925.

28. O Lillie E, Patay B, Diamant J et al. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per Med 2011; 8(2): 161–173.

29. Nalysnyk L, Hemandez-Medina M, Krishnarajah G. Glycamic variability and complications in patients with diabetes mellitus: evidence from systemic review of the literature. Diabetes Obes Metab 2012; 12(4): 288–298.

30. Monnier L, Colette C. Glycemic variability: should we and can we prevent it? Diabetes Care 2008; 31(Suppl 2): S150-S154.

31. DeFronzo RA. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes 2009, 58(4): 773–796.

32. Kahn SE, Cooper ME, Del Prato S. Pathopysiology and treatment of type 2 diabetes: perspectives on the past, present and future. Lancet 2014; 383(9922): 1068–1083.

33. Haluzík M. Průvodce léčbou diabetu 2. typu pro internisty. Mladá fronta: Praha 2015. ISBN 978–80–204–2405–1.

34. Del Prato S, LaSalle J, Matthaei S et al. Global Partnership for Effective Diabetes Management. Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Parthership for Effective Diabetes Management. Int J Clin Pract 2010; 64(3): 295–304.

35. Viberti G, Kahn SE, Greene DA et al. A Diabetes Outcome Progression Trial (ADOPT). An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25(10): 1737–1743.

36. Okša A, Ponťuch P, Spustová V et al. Diabetická nefropatia: Diagnostika, prevencia a liečba. Odporúčané postupy Slovenskej nefrologickej spoločnosti a Slovenskej diabetologickej spoločnosti. Forum Diab 2013; 2(Suppl 1): S1-S6.

37. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl (2011) 2013; 3(1): 5–14.

38. Haluzík M. Léčba diabetiků s chronickým onemocněním jater. In: Haluzík M, Rychlík I (eds). Léčba pacientů s onemocněním ledvin a jater. Mladá fronta: Praha 2012: 115–125. ISBN 978–80–204–2671–0.

39. Romeo GR., Abrahamson MJ, Goldfine AB. Insulin Segretagogues: Sulfonylureas and Glinides. In: Umpierrez GE (ed) Therapy for Diabetes Mellitus and Related Disorders. 6th ed. American Diabetes Association 2014: 359–376. ISBN 978–1580405096.

40. Zoungas S, Chalmers J, Neal B et al. ADVANCE-ON Collaborative Group. Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. N Engl J Med 2014; 371(15):1392–1406.

41. Chiasson JL, Josse RG, Gomis R et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359(8323):2072–2077.

42. Kuo HW, Tiao MM, Ho SC, Yang CY. Pioglitazone use and the risk of bladder cancer. Kaohsiung J Med Sci 2014; 30(2): 94–97.

43. Schroner Z, Uličiansky V. Inhibítory dipeptidyl-peptidázy-4 – základná charakteristika a mechanizmus účinku. In: Schroner Z, Uličiansky V. Liečba diabetes mellitus 2. typu založená na účinku inkretínov. 2. rozšírené vyd. SchronerMed: Košice 2011: 41–62.ISBN 9788097071479.

44. Egan AG, Blind E, Dunder K et al. Pancreatic safety of incretin-based drugs. FDA and EMA assessment. N Engl J Med 2014; 370(9): 794–797.

45. Štulc T, Šedo A. Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract 2010; 88(2): 125–131.

46. Marfella R, Barbieri M, Grella R et al. Effects of vildagliptin twice daily vs sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications 2010; 24(2): 79–83.

47. Schweizer A, Dejager S, Foley JE et al. Assesing the cardio-vascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab 2010; 12(6): 485–494.

48. White WB, Cannon CHP, Heller SR et al. EXAMINE Investigators. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med 2013; 369(14): 1327–1335.

49. Scirica BM, Bhatt DL, Braunwald E et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med 2013; 369(14):1317–1326.

50. Nainggolan L. TECOS: No Increase in HF Hospitalization With Sitagliptin. Medscape Medical News. Dostupné z WWW: <http://www.medscape.com/viewarticle/843830>.

51. Bays H. Sodium Glucose Co-transporter Type 2 (SGLP2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus. Diabetes Ther 2013; 4(2): 195–220.

52. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012; 14(1): 5–14.

53. Schroner Z. SGLT-2 inhibítory a iné nové trendy liečby diabetes mellitus 2. typu. In: Uličiansky V, Schroner Z, Galajda P et al. Diabetes mellitus v zrelom veku. Martin: Quick Print 2013: 93–106.

54. Uličiansky V. Nová stratégia v liečbe diabetu mellitus 2. typu – inhibícia renálnej reabsorpcie glukózy. Interná Med 2014; 14(4): 179–185.

55. Bolinder J, Ljunggren O, Kullberg J et al. Effects of dapagliflozin on body weight, total fat mass and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97(3): 1020–1031.

56. Schroner Z, Uličiansky V. Nová cesta v liečbe diabetes mellitus 2. typu – SGLT2 inhibítory. Diabetes a obezita 2014; 14(28): 31–35.

57. Stenlof K, Cefalu WT, Kim KA et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15(4): 372–382.

58. Galajda P, Samoš M, Mokáň M et al. Nový SGLT2 inhibítor – empagliflozín. Diabetes a obezita 2014; 14(28): 37–46.

59. Häring HU, Merker L, Seewald-Becker E et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2013; 36(11): 3396–3404.

60. Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med 2009; 122(Suppl 6):S37-S50.

61. Nauck M, Smith U. Increatin- based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients? Best Pract Res Clin Endocrinol Metab 2009; 23(4): 513–523.

62. Buse J, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374(9683): 39–47.

63. Stonehouse A, Walsh B, Cuddihy R. Exenatide Once-Weekly Clinical Development. Safety and Efficacy Across a Range of Background Therapies. Diabetes Technol Ther 2011; 13(10): 1063–1069.

64. Meier JJ. GLP‑1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8(12):728–742.

65. Horowitz M, Rayner CK, Jones KL. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. Adv Ther 2013; 30(2):81–101.

66. Owens DR. Stepwise intensification of insulin therapy in Type 2 diabetes management – exploring the concept of the basal-plus approach in clinical practice. Diabet Med 2013; 30(3): 276–288.

67. Fonseca V, Davidson J, Home P et al. Startins insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-targe trials. Curr Med Res Opin 2010; 26(7): 1621–1628.

68. Martinka E. Liečba inzulínom u pacientov s diabetes melltius 2. typu. In: Mokáň M, Martinka E, Galajda P a kol: Diabetes mellitus a vybrané metabolické ochorenia. Vydavateľstvo P+M: Martin 2008: 323–331. ISBN 978–80–969713–9-8,

69. Halimi S, Raskin P, Liebl A et al. Efficacy of biphasic insulin aspart in patients with type 2 diabetes. Clin Ther 2005; 27(Suppl B): S57-S74.

70. Holman RR, Thorne KI, Farmer AJ et al. 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357(17): 1716–1730.

71. Holst JJ, Vilsboll T. Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes Obes Metab 2013; 15(1): 3–14.

72. Ratner RE, Gough SC, Mathieu C et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013; 15(2): 175–184.

73. Gerstein HC, Bosch J, Dagenais GR et al. The ORIGIN Trial Investigators. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. N Eng J Med 2012; 367(4): 319–328.

Labels
Diabetology Endocrinology Internal medicine
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#